Fidson Healthcare Plc has entered into a Memorandum of Understanding (MoU) with Japanese pharmaceutical company, Ohara Pharmaceutical Co. Ltd, in a move expected to strengthen research, production, and distribution capacity in Nigeria’s healthcare sector.
The agreement, signed in Lagos on Thursday, will facilitate collaboration in the areas of technology transfer, joint product development, and capacity building for local pharmaceutical manufacturing. Fidson said the partnership would enable it to expand its product portfolio, improve access to essential medicines, and enhance quality assurance in line with international standards.
Managing Director and Chief Executive Officer of Fidson Healthcare, Dr. Fidelis Ayebae, described the deal as a milestone that underscores the company’s commitment to innovation and global partnerships. He noted that the collaboration with Ohara would help address Nigeria’s drug supply challenges while boosting self-sufficiency in local production.
Representatives of Ohara emphasized that the partnership reflects their long-term interest in African markets, with Nigeria serving as a strategic entry point. They added that the alliance would contribute to knowledge sharing, workforce training, and broader investment opportunities in the pharmaceutical space.
Analysts believe the MoU could position Fidson more competitively within the Nigerian healthcare market by improving product availability and affordability. It also aligns with the Federal Government’s drive to encourage local manufacturing and reduce dependence on imported medicines.
